Targeted Inhibition of Multiple Receptor Tyrosine Kinases in Mesothelioma

Craighead, 1987, Current pathogenetic concepts of diffuse malignant mesothelioma, Hum Pathol, 18, 544, 10.1016/S0046-8177(87)80354-4 Sahin, 1993, Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients, AJR Am J Roent-genol, 161, 533, 10.2214/ajr.161.3.8394641 Carbone, 2003, New developments about the association of SV40 with human mesothelioma, Oncogene, 22, 5173, 10.1038/sj.onc.1206552 Peto, 1995, Continuing increase in mesothelioma mortality in Britain, Lancet, 345, 535, 10.1016/S0140-6736(95)90462-X Pache, 1998, Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers, Am J Pathol, 152, 333 Zanella, 1996, Asbestos causes stimulation of the extracellular signal–regulated kinase 1 mitogen–activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor, Cancer Res, 56, 5334 Janne, 2002, Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma, Cancer Res, 62, 5242 Tolnay, 1998, Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma, J Cancer Res Clin Oncol, 124, 291, 10.1007/s004320050171 Klominek, 1998, Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor, Int J Cancer, 76, 240, 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G Jagadeeswaran, 2006, Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma, Cancer Res, 66, 352, 10.1158/0008-5472.CAN-04-4567 Mukohara, 2005, Inhibition of the met receptor in mesothelioma, Clin Cancer Res, 11, 8122, 10.1158/1078-0432.CCR-05-1191 Cacciotti, 2001, SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma, Proc Natl Acad Sci USA, 98, 12032, 10.1073/pnas.211026798 Xia, 2005, Up-regulation of EphB4 in mesothelioma and its biological significance, Clin Cancer Res, 11, 4305, 10.1158/1078-0432.CCR-04-2109 Ohta, 1999, VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours, Br J Cancer, 81, 54, 10.1038/sj.bjc.6690650 Strizzi, 2001, Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma, J Pathol, 193, 468, 10.1002/path.824 Lee, 1993, Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules, Cancer Res, 53, 2858 Pass, 1996, Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor, Cancer Res, 56, 4044 Pegram, 1998, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti–p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu–overexpressing metastatic breast cancer refractory to chemotherapy treatment, J Clin Oncol, 16, 2659, 10.1200/JCO.1998.16.8.2659 Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N Engl J Med, 347, 472, 10.1056/NEJMoa020461 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Gordon, 2005, Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am J Pathol, 166, 1827, 10.1016/S0002-9440(10)62492-3 Rubin, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res, 61, 8118 Workman, 2004, Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone, Cancer Lett, 206, 149, 10.1016/j.canlet.2003.08.032 Gschwind, 2004, The discovery of receptor tyrosine kinases: targets for cancer therapy, Nat Rev Cancer, 4, 361, 10.1038/nrc1360 Govindan, 2005, Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B, Clin Cancer Res, 11, 2300, 10.1158/1078-0432.CCR-04-1940 Mathy, 2005, Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, 50, 83, 10.1016/j.lungcan.2005.04.010 Harvey, 2000, Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases, Br J Cancer, 83, 1147, 10.1054/bjoc.2000.1445 Destro, 2006, EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations, Lung Cancer, 51, 207, 10.1016/j.lungcan.2005.10.016 Kawaguchi, 2009, Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells, Carcinogenesis, 30, 1097, 10.1093/carcin/bgp097 Janssen, 1991, A novel putative tyrosine kinase receptor with oncogenic potential, Oncogene, 6, 2113 O’Bryan, 1991, axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase, Mol Cell Biol, 11, 5016, 10.1128/MCB.11.10.5016 Sreedhar, 2004, Inhibition of Hsp90: a new strategy for inhibiting protein kinases, Biochim Biophys Acta, 1697, 233, 10.1016/j.bbapap.2003.11.027 Sreedhar, 2004, Hsp90 isoforms: functions, expression and clinical importance, FEBS Lett, 562, 11, 10.1016/S0014-5793(04)00229-7 Sharp, 2006, Inhibitors of the HSP90 molecular chaperone: current status, Adv Cancer Res, 95, 323, 10.1016/S0065-230X(06)95009-X Isaacs, 2003, Heat shock protein 90 as a molecular target for cancer therapeutics, Cancer Cell, 3, 213, 10.1016/S1535-6108(03)00029-1 Waza, 2005, 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration, Nat Med, 11, 1088, 10.1038/nm1298 Csermely, 1998, The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review, Pharmacol Ther, 79, 129, 10.1016/S0163-7258(98)00013-8 Sydor, 2006, Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90, Proc Natl Acad Sci USA, 103, 17408, 10.1073/pnas.0608372103 Okamoto, 2008, Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma, J Thorac Oncol, 3, 1089, 10.1097/JTO.0b013e3181839693 Baldi, 2002, Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival, Thorax, 57, 353, 10.1136/thorax.57.4.353 Bongiovanni, 2001, p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma, Cancer, 92, 1245, 10.1002/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G